Patient-specific melanoma-associated antigens and neoantigens

Patient-specific melanoma-associated antigens and neoantigens are a personalized collection of proteins expressed by an individual's own tumor-initiating melanoma cells (TIMCs). These antigens encompass both shared melanoma-associated antigens (MAAs) and unique neoantigens that arise from somatic mutations specific to the patient's tumor. TIMCs are characterized as the "seed" or "root" of the cancer, possessing stem-cell-like properties that enable them to drive tumor progression, metastasis, and resistance to standard therapies. In clinical applications, such as the AV-MEL (DC-ATA) vaccine platform, autologous dendritic cells are pulsed with these antigens to prime the patient's immune system to recognize and eliminate the TIMC population. By targeting the cells responsible for self-renewal and recurrence, this approach aims to induce a durable and comprehensive anti-tumor immune response. Research often explores the use of these antigens in combination with immune checkpoint inhibitors to overcome local immunosuppression and enhance therapeutic efficacy.

Other names

Autologous tumor antigensTumor-initiating cell antigensMelanoma neoantigensCancer stem cell antigensDC-ATA antigensPersonalized melanoma antigens

Stimulation of a patient-specific cytotoxic T-lymphocyte response by loading autologous dendritic cells with a broad spectrum of antigens derived from self-renewing tumor-initiating cells to target the source of tumor growth and recurrence.